Since the first approval of a targeted therapy in patients with NSCLC (erlotinib in epidermal growth factor receptor [EGFR]-positive disease) in 2013, molecular testing has evolved into an essential component of patient care with the National Comprehensive Cancer Network currently advising for broad molecular profiling to assess nine predictive biomarkers, at least, at baseline [3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.